Sclerostin quo vadis? -Is this a useful long-term mortality parameter in prevalent hemodialysis patients?

Kidney and Blood Pressure Research

Volumn 40, Issue 3, 2015, Pages 266-276

  Nowak, Albina ^a   Artunc, Ferruh ^b   Serra, Andreas L ^c   Pollock, Emily ^a   Krayenbühl, Pierre Alexandre ^a   Müller, Christian ^d   Friedrich, Björn ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Dialysis Center   (Germany)

Author keywords

Cardiovascular; Hemodialysis; Mortality; Sclerostin

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GENETIC MARKER; HYDROXYCOLECALCIFEROL; SOST PROTEIN, HUMAN;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SURVIVOR; VITAMIN BLOOD LEVEL; ADULT; BLOOD; BONE REMODELING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; GENETIC MARKER; HEMODIALYSIS; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PREVALENCE; TREATMENT OUTCOME;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOMARKERS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; HYDROXYCHOLECALCIFEROLS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84929688970     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368502     Document Type: Article

References (38)

1. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, Safford MM, Zhang X, Muntner P, Warnock D: Detection of chronic kidney disease with creatinine, cystatin C, and urine albuminto-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011;305:1545-1552.
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global O: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
3. Ke HZ, Richards WG, Li X, Ominsky MS: Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012;33:747-783.
4. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-543.
5. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM: Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005;15:928-935.
6. Kim SJ, Bieganski T, Sohn YB, Kozlowski K, Semenov M, Okamoto N, Kim CH, Ko AR, Ahn GH, Choi YL, Park SW, Ki CS, Kim OH, Nishimura G, Unger S, Superti-Furga A, Jin DK: Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet 2011;129:497-502.
7. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE: The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011;6:e19595.
8. Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P, Evenepoel P: Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab 2013;98:3221-3228.
9. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA: Early chronic kidney diseasemineral bone disorder stimulates vascular calcification. Kidney Int 2014;85:142-150.
10. Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, Rozas-Moreno P, Garcia-Salcedo JA, Reyes-Garcia R, Munoz-Torres M: Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013;36:1667-1674.
11. Nowak A, Friedrich B, Artunc F, Serra AL, Breidthardt T, Twerenbold R, Peter M, Mueller C: Prognostic Value and Link to Atrial Fibrillation of Soluble Klotho and FGF23 in Hemodialysis Patients. PLoS One 2014;9:e100688.
12. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Peter A, Thamer C, Weyrich P, Haering HU, Friedrich B: Sensitive troponins-which suits better for hemodialysis patients? Associated factors and prediction of mortality. PLoS One 2012;7:e47610.
13. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Rettig I, Usta E, Haring HU, Friedrich B: Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker? Kidney Blood Press Res 2012;36:172-181.
14. Artunc F, Nowak A, Mueller C, Breidthardt T, Twerenbold R, Wagner R, Peter A, Haering HU, Ebmeyer S, Friedrich B: Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality. PLoS One 2014;9:e86148.
15. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC: Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013;28:3024-3030.
16. Kanbay M, Siriopol D, Saglam M, Gulcan Kurt Y, Gok M, Cetinkaya H, Karaman M, Umut Unal H, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Ilker Yilmaz M: Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients. J Clin Endocrinol Metab 2014, DOI 10.1210/jc.2014-2042jc20142042.
17. Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM, for the NSG: High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2014, DOI 10.1093/ ndt/gfu301.
18. Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, Bruyere O, Reginster JY, Pottel H, Cavalier E: Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 2014;128:127-134.
19. Costa AG, Cremers S, Dworakowski E, Lazaretti-Castro M, Bilezikian JP: Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int 2014;25:1547-1554.
20. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D: The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013;8:819-823.
21. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD: Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009;284:10890-10900.
22. Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M: Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014;99:248-255.
23. Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wuthrich RP: Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 2014;39:230-239.
24. Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M: Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 2013;14:219.
25. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC: Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012;27:1757-1772.
26. Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA: CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKDMineral and Bone Disorder. J Am Soc Nephrol 2014;25:1760-1773.
27. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M: Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010;9:2048-2062.
28. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-1378.
29. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T: Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008;3:e2942.
30. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE: Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005;95:1178-1190.
31. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-4583.
32. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S: Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010;95:5056-5062.
33. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort Study G: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-2439.
34. Etter C, Straub Y, Hersberger M, Raz HR, Kistler T, Kiss D, Wuthrich RP, Gloor HJ, Aerne D, Wahl P, Klaghofer R, Ambuhl PM: Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis. Eur Heart J 2010;31:354-359.
35. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
36. Tong LL, Mehrotra R, Shavelle DM, Budoff M, Adler S: Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient. Hemodial Int 2008;12:16-22.
37. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L: Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001;60:257-265.
38. Maruyama Y, Taniguchi M, Kazama JJ, Yokoyama K, Hosoya T, Yokoo T, Shigematsu T, Iseki K, Tsubakihara Y: A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant 2014;29:1532-1538.